Comparison Of Doacs Available For Vte Prophylaxis

Comparison of DOACs Available for VTE Prophylaxis

Selecting & Utilizing a DOAC for VTE Prophylaxis

New Agents for DVT Prophylaxis: Should They Be Utilized

ClevelandClinicCME

VTE Prevention Across the Continuum: A Focus on Extended Prophylaxis

Oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism

Anticoagulation Treatment - The key to managing VTE explained

Update in the use of DOACs and mechanical thromboprophylaxis

DOACs, NOACs, and Coumadin in DVT, My Approach in 2020-Rajesh Swaminathan, MD

Cardiovascular Innovations

DOAC VTE Prophylaxis for Patients with Cancer

Medication Quality and Safety Rx

Webinar | What's New in Anticoagulation Therapy?

Omnicare, a CVS Health company

DVT/PE Diagnosis and Management, Including NOACs - Marc Carrier MD

University of Ottawa Heart Institute

DOACs in Elderly Patients and Extremes of Weight

ThrombosisCanada

VTE prevention in the medically ill - is there a role for DOACs

Society for Vascular Medicine

The Evolving Role of DOACs in the Management of Venous and Arterial Disease

Cancer-Associated Thrombosis and Antiphospholipid Syndrome: An Update for Clinicians

NOAC vs Warfarin, Current Status of Venous Anticoagulation (Baltazar MD; Petkova MD) March 24, 2021

Houston Methodist DeBakey CV Education

Direct Oral Anticoagulants Presentation - Philip S. Wells, MD

University of Ottawa Heart Institute

Direct Oral Anticoagulants Compared With Dalteparin for TX of Cancer-Associated Thrombosis

Mayo Proceedings

10 Clinical Minutes: VTE Prophylaxis

Direct Oral Anticoagulants (DOAC): A review